Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence

BJU International

Volumn 116, Issue 4, 2015, Pages 556-567

  Alshalalfa, Mohammed ^a   Crisan, Anamaria ^a   Vergara, Ismael A ^a   Ghadessi, Mercedeh ^a   Buerki, Christine ^a   Erho, Nicholas ^a   Yousefi, Kasra ^a   Sierocinski, Thomas ^a   Haddad, Zaid ^a   Black, Peter C ^b   Karnes, R Jeffrey ^c   Jenkins, Robert B ^c   Davicioni, Elai ^a  

^a GenomeDx Biosciences Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

biochemical recurrence; gene expression; gene functional analysis; metastasis; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RNA; TRANSCRIPTOME; UNTRANSLATED RNA;

ARTICLE; BIOCHEMICAL RECURRENCE; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENOME ANALYSIS; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; METASTASIS POTENTIAL; ONCOGENE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN PROTEIN INTERACTION; TUMOR RECURRENCE;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN INTERACTION MAPS; RNA, UNTRANSLATED; TRANSCRIPTOME;

EID: 84941183883     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13013     Document Type: Article

References (29)

1. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109: 32-9
2. Punnen S, Cooperberg MR, D'Amico AV, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013; 64: 905-15
3. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM,. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4: 127rv3
4. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
5. Nakagawa T, Kollmeyer TM, Morlan BW, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008; 3: e2318
6. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61: 1096-106
7. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013; 8: e66855
8. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013; 190: 2047-53
9. Wu G, Feng X, Stein L,. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010; 11: R53
10. Schroeck FR, Aronson WJ, Presti JC, et al. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int 2009; 103: 603-8
11. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22
12. Sartor MA, Mahavisno V, Keshamouni VG, et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 2010; 26: 456-63
13. Swanson GP, Basler JW,. Prognostic factors for failure after prostatectomy. J Cancer. Ivyspring International Publisher 2010; 2: 1-19
14. Xia J, Trock BJ, Gulati R, et al. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res 2014; 20: 5302-10
15. Davis J,. Novel commercially available genomic tests for prostate cancer: a road map to understanding their clinical impact. BJUi 2014; 114: 320-2
16. Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol [Internet] 2014; 89: 1038-46. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0360301614005525
17. Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2014; doi: 10.1016/j.eururo.2014.10.036. [Epub ahead of print]
18. Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis [Internet] 2014; 17: 64-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24145624
19. Prensner JR, Iyer MK, Balbin OA,. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013; 45: 1392-8
20. Vergara IA, Erho N, Triche TJ, et al. Genomic "Dark Matter" in prostate cancer: exploring the clinical utility of ncRNA as biomarkers. Front Genet 2012; 3: 23
21. Sun Y, Wang B-E, Leong KG, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012; 72: 527-36
22. Nelles JL, Hu W-Y, Prins GS,. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 2011; 6: 437-51
23. Bardelle C, Boros J,. Development of a high-content high-throughput screening assay for the discovery of ATM signaling inhibitors. J Biomol Screen 2012; 17: 912-20
24. Wang Y-G, Nnakwe C, Lane WS, Modesti M, Frank KM,. Phosphorylation and regulation of DNA ligase IV stability by DNA-dependent protein kinase. J Biol Chem 2004; 279: 37282-90
25. Hoque MT, Ishikawa F,. Human chromatid cohesin component hRad21 is phosphorylated in M phase and associated with metaphase centromeres. J Biol Chem 2001; 276: 5059-67
26. Bayliss R, Sardon T, Vernos I, Conti E,. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003; 12: 851-62
27. Baccarini M,. Second nature: biological functions of the Raf-1 "kinase". FEBS Lett 2005; 579: 3271-7
28. Sweeney C, Chen Y-H, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32 (suppl; abstr LBA2): 5s
29. Aparicio A, Logothetis CJ, Maity SN,. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011; 1: 466-8